Patents by Inventor Niko Schmiedeberg

Niko Schmiedeberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic compounds and their uses
    Patent number: 11878973
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 23, 2024
    Assignee: NOVARTIS AG
    Inventors: Vincent Bordas, Jvan Brun, Markus Furegati, Jacques Hamon, Jürgen Hans-Hermann Hinrichs, Philipp Holzer, Fatma Limam, Henrik Möbitz, Sandro Nocito, Simone Plattner, Niko Schmiedeberg, Joseph Schoepfer, Ross Sinclair Strang, Frédéric Zecri
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives
    Publication number: 20230398117
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: December 1, 2022
    Publication date: December 14, 2023
    Inventors: Luca ARISTA, Christina HEBACH, Gregory John HOLLINGWORTH, Philipp HOLZER, Patricia IMBACH-WEESE, Rainer MACHAUER, Niko SCHMIEDEBERG, Anna VULPETTI, Thomas ZOLLER
  • Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
    Patent number: 11613543
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 28, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Bicyclic Compounds and their Uses
    Publication number: 20230046859
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Application
    Filed: May 25, 2022
    Publication date: February 16, 2023
    Inventors: Vincent BORDAS, Jvan BRUN, Andrea DECKER, Markus FUREGATI, Geoffrey GOGNIAT, Wanben GONG, Jacques HAMON, Jürgen Hans-Hermann HINRICHS, Philipp HOLZER, Fatma LIMAM, Henrik MÖBITZ, Sandro NOCITO, Simone PLATTNER, Niko SCHMIEDEBERG, Joseph SCHOEPFER, Jessica SOTO, Ross Sinclair STRANG, Shuping YAO, Huangchao YU, Frédéric ZECRI, Sisi ZHANG
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
    Patent number: 11541056
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: January 3, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives
    Publication number: 20210251996
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 19, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives
    Publication number: 20210002285
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Naphthyridinedione derivatives
    Publication number: 20190248784
    Abstract: The invention relates to compound of the formula (I?) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: October 10, 2018
    Publication date: August 15, 2019
    Inventors: Juergen REINHARDT, Niko SCHMIEDEBERG, Carsten SPANKA
  • Naphthyridinedione derivatives
    Patent number: 10138232
    Abstract: The invention relates to compound of the formula (I?) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: November 27, 2018
    Assignee: NOVARTIS AG
    Inventors: Juergen Reinhardt, Niko Schmiedeberg, Carsten Spanka
  • Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
    Patent number: 9896448
    Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 20, 2018
    Assignee: NOVARTIS AG
    Inventor: Niko Schmiedeberg
  • Pyridopyrimidinedione derivatives
    Patent number: 9884862
    Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 6, 2018
    Assignee: Novartis AG
    Inventors: Niko Schmiedeberg, Carsten Spanka
  • Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones
    Publication number: 20170266189
    Abstract: The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 4, 2017
    Publication date: September 21, 2017
    Inventors: Edgar JACOBY, Juergen REINHARDT, Niko SCHMIEDEBERG, Carsten SPANKA
  • Pyridopyrimidinedione derivatives
    Publication number: 20170197959
    Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: June 2, 2015
    Publication date: July 13, 2017
    Applicant: Novartis AG
    Inventors: Juergen REINHARDT, Niko SCHMIEDEBERG, Carsten SPANKA
  • Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione derivatives
    Publication number: 20170183341
    Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: June 2, 2015
    Publication date: June 29, 2017
    Applicant: Novartis AG
    Inventors: Juergen REINHARDT, Niko SCHMIEDEBERG
  • Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones
    Patent number: 9649314
    Abstract: The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: May 16, 2017
    Assignee: NOVARTIS AG
    Inventors: Edgar Jacoby, Juergen Reinhardt, Niko Schmiedeberg, Carsten Spanka
  • Naphthyridinedione derivatives
    Publication number: 20150344476
    Abstract: The invention relates to compound of the formula (I?) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 3, 2015
    Applicant: NOVARTIS AG
    Inventors: Juergen REINHARDT, Niko SCHMIEDEBERG, Carsten SPANKA
  • Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones
    Publication number: 20150335646
    Abstract: The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: December 12, 2013
    Publication date: November 26, 2015
    Applicant: NOVARTIS AG
    Inventors: Edgar JACOBY, Juergen INHARDT, Niko SCHMIEDEBERG, Carsten SPANKA
  • HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS
    Publication number: 20100261758
    Abstract: Compounds of Formula (I) wherein R1 is aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R2 is defined heterocyclyl, R3 is alkyl, aryl, cyclohexyl or heterocyclyl, or (C1-4)alkyl substituted by aryl, cyclohexyl or heterocyclyl, R4 is H or alkyl, or R3 and R4 together with the carbon atom to which they are attached are cycloalkyl fused with aryl, and their use as pharmaceuticals.
    Type: Application
    Filed: March 28, 2007
    Publication date: October 14, 2010
    Applicant: NOVARTIS AG
    Inventors: Luca Arista, Klemens Hogenauer, Niko Schmiedeberg, Gudrun Werner, Herbert Jaksche
  • 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors
    Publication number: 20080275054
    Abstract: The invention relates to novel pyrazolo[3,4-d]pyrimidines of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: November 28, 2006
    Publication date: November 6, 2008
    Inventors: Philipp Holzer, Patricia Imbach, Pascal Furet, Niko Schmiedeberg
  • 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors
    Publication number: 20080096868
    Abstract: The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I, pharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine compound, methods for the manufacture of a novel compound of that class, and novel intermediates and partial steps for their synthesis.
    Type: Application
    Filed: November 10, 2005
    Publication date: April 24, 2008
    Inventors: Niko Schmiedeberg, Pascal Furet, Patricia Imbach, Philipp Holzer